SCHEMBL23833335

SCHEMBL23833335

CC(C)(C)[Si](OC[C@H]1CC[C@@H](CO)CC1)(c1ccccc1)c1ccccc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMYD2 Q9NRG4 3/20 0.37
RIPK1 Q13546 1/20 0.36
GABRA1 P14867 1/20 0.35
GABRG2 P18507 1/20 0.35
GABRB3 P28472 1/20 0.35
GABRA5 P31644 1/20 0.35
GABRA3 P34903 1/20 0.35
GABRA2 P47869 1/20 0.35
CYP3A4 P08684 2/20 0.35
HTT P42858 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
CHRM2 P08172 1/20 0.34
CHRM1 P11229 1/20 0.34
CHRM3 P20309 1/20 0.34
MGAM O43451 1/20 0.32
ESR1 P03372 1/20 0.32
CYP2C9 P11712 1/20 0.32
ESR2 Q92731 1/20 0.32
LTA4H P09960 1/20 0.31
HTR2C P28335 3/20 0.31

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23517183 1.00 SMYD2 (0.37) SMYD2RIPK1GABRA1GABRG2GABRB3
SCHEMBL2914349 0.92 RIPK1 (0.41) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL30879353 0.92 SMYD2 (0.36) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL27039408 0.90 SMYD2 (0.41) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL15822127 0.88 SMYD2 (0.37) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL30078357 0.88 SMYD2 (0.37) SMYD2CYP3A4HTTSMN1; SMN2MGAM
SCHEMBL27156635 0.88 SMYD2 (0.37) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL15822129 0.88 SMYD2 (0.37) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL10380887 0.86 SMYD2 (0.39) SMYD2RIPK1CYP3A4HTTSMN1; SMN2
SCHEMBL4381700 0.86 SMYD2 (0.35) SMYD2CYP3A4HTTSMN1; SMN2CHRM3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. 2024-01-18 US disclosed
EP-4121055-A1 STAT DEGRADERS AND USES THEREOF Kymera Therapeutics, Inc. (US) 2023-01-25 EP disclosed
WO-2021188696-A1 STAT DEGRADERS AND USES THEREOF KYMERA THERAPEUTICS, INC. (US) 2021-09-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240016942-A1 STAT DEGRADERS AND USES THEREOF STAT4, STAT1, STAT3 SMYD2 2720/4885RIPK1 2012/4885GABRA1 2966/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.